Patents by Inventor LuZhe Sun

LuZhe Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STEAP2 inhibitors for the treatment of liver cancers
    Patent number: 11168327
    Abstract: Provided are methods for the diagnosis and treatment of liver cancers such as hepatocellular carcinoma (HCC). In some aspects, the methods comprise administering an inhibitor of STEAP2 to a subject to treat a liver cancer. In some embodiments, a STEAP2 targeting siRNA or antibody is administered to a subject to treat HCC.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: November 9, 2021
    Assignee: Research Development Foundation
    Inventors: Luzhe Sun, Carla Zeballos Torrez, Xiang Gu, Francisco Cigarroa
  • STEAP2 INHIBITORS FOR THE TREATMENT OF LIVER CANCERS
    Publication number: 20190352646
    Abstract: Provided are methods for the diagnosis and treatment of liver cancers such as hepatocellular carcinoma (HCC). In some aspects, the methods comprise administering an inhibitor of STEAP2 to a subject to treat a liver cancer. In some embodiments, a STEAP2 targeting siRNA or antibody is administered to a subject to treat HCC.
    Type: Application
    Filed: January 31, 2018
    Publication date: November 21, 2019
    Applicant: Research Development Foundation
    Inventors: Luzhe SUN, Carla Zeballos TORREZ, Xiang GU, Francisco CIGARROA
  • TGFß TYPE II-TYPE III RECEPTOR FUSIONS
    Publication number: 20170166624
    Abstract: Certain embodiments are directed to TGF-? inhibitors EUc and REUc. EUc is generated by removing the non-binding N-terminal subdomain from the TGF-? type III receptor, and REUc is generated by fusing together the binding domains of the TGF-? type II (RII or R) and type III receptor (RIII or EU) by a flexible linker and by removing the non-binding N-terminal subdomain from the TGF-? type III receptor.
    Type: Application
    Filed: July 14, 2015
    Publication date: June 15, 2017
    Inventors: Andrew Hinck, LuZhe Sun, Christian Zwieb
  • TGFB type II-type III receptor fusions
    Patent number: 9611306
    Abstract: Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-? type II receptor (T?P?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-? type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-? type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-? type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-? isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-? isoforms, but not other ligands of the TGF-? superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: April 4, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew Hinck, Luzhe Sun, Christian Zwieb
  • Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
    Patent number: 7795389
    Abstract: Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGF?) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: September 14, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: LuZhe Sun, Andrew P. Hinck
  • Antagonizing TGF-beta activity with various ectodomains of TGF-beta receptors used in combination or as fusion proteins
    Publication number: 20070244042
    Abstract: Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGF?) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.
    Type: Application
    Filed: September 28, 2005
    Publication date: October 18, 2007
    Inventors: LuZhe Sun, Andrew Hinck